XORTX Therapeutics Inc.

Company Profile

Sector

Healthcare

Industry

Biotechnology

Employees

N/A

Website

www.xortx.com

Country

Canada

Exchange

TSXV

XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company provides the development and commercialization of therapies to treat hyperuricemia related diseases in Canada. It develops XRx-026, which is in Phase III for the treatment of gout.

Its portfolio also includes XRx-008, which is in Phase II for the treatment of autosomal dominant polycystic kidney disease, XRx-101, which is in Phase II for the treatment of acute kidney injury associated with respiratory virus infection

Including sepsis and coronavirus, and XRX-225, which is in preclinical stage for the treatment of type 2 diabetic nephropathy VB4-P5, a program for the treatment and prevention of fibrosis in the kidney. The company is based in Calgary, Canada.

Key Stats

52-Week Range

C$2.42C$9.85

Beta0.17

Trailing P/EN/A

Forward P/E2.58

Trailing EPS-3.46

Avg Volume

Earnings & Analyst

Next Earnings2026-08-13

EPS EstimateN/A

Target Mean PriceN/A

RecommendationNone

Recommendation MeanN/A

Recent SEC Filings

SEC filings for this ticker are not available yet.